Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 17/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105367 | 0.93 | P2RX3 (0.43) | P2RX3ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22105785 | 0.91 | P2RX3 (0.44) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL22105575 | 0.90 | P2RX3 (0.45) | P2RX3 | |
| SCHEMBL22105468 | 0.90 | P2RX3 (0.44) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL22111541 | 0.90 | P2RX3 (0.51) | P2RX3NPSR1 | |
| SCHEMBL20653062 | 0.90 | P2RX3 (0.46) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL22105461 | 0.89 | P2RX3 (0.44) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL22105810 | 0.88 | P2RX3 (0.42) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL22105736 | 0.88 | P2RX3 (0.44) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL20652978 | 0.88 | P2RX3 (0.47) | P2RX3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | P2RX3 9/4885NPSR1 184/4885ALDH1A1 869/4885 |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | TRPC5, TRPM5, TRPC4 | P2RX3 24/4885NPSR1 289/4885ALDH1A1 1568/4885 |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | P2RX3 9/4885NPSR1 208/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.